Rationale: Heart failure (HF) is known to be associated with increased Ca 2؉ /calmodulin-dependent protein kinase (CaMK)II expression and activity. There is still controversial discussion about the functional role of CaMKII in HF. Moreover, CaMKII inhibition has never been investigated in human myocardium.
H eart failure (HF) is accompanied by systolic and diastolic contractile dysfunction caused by abnormalities in intracellular Ca 2ϩ handling and structural remodeling. Several targets associated with the remodeling processes have been identified. The sarcoplasmic reticulum (SR) Ca 2ϩ -ATPase (SERCA) protein levels have been reported to be downregulated and paralleled by a reduced SR Ca 2ϩ uptake capacity in the human failing heart. [1] [2] [3] In contrast, the sarcolemmal Na ϩ /Ca 2ϩ exchanger protein expression and activity were found to be increased thereby even more effectively competing with the reduced SERCA activity for cytosolic Ca 2ϩ -removal. 3, 4 The net effect is an impaired SR Ca 2ϩ loading, which leads to smaller intracellular Ca 2ϩ transients and elevated diastolic Ca 2ϩ levels in HF. 5 Thus, impaired contractility with reduced contractile force and diastolic dysfunction are well-accepted determinants in HF. 6 Intracellular Ca 2ϩ homeostasis of cardiac myocytes is also regulated by phosphorylation of several key Ca 2ϩ -handling proteins. An important regulatory kinase is the Ca 2ϩ /calmodulin-dependent protein kinase (CaMK)II. 7 It is a serine/ threonine protein kinase that modulates several intracellular Ca 2ϩ -handling proteins such as SR Ca 2ϩ -release channels (ryanodine receptors, RyR2), phospholamban (PLB), and L-type Ca 2ϩ channels (LTCCs) but also Na ϩ channels. 7 The predominant cardiac isoform is CaMKII␦, with the splice variant ␦ C being primarily cytosolic and ␦ B being localized to the nucleus. 8, 9 Because CaMKII accelerates relaxation via PLB phosphorylation and increased CaMKII protein levels correlate positively with impaired ejection fraction in the myocardium of patients with HF, it was proposed that elevated CaMKII expression and activity may be a compensatory mechanism to keep hearts from complete failure. 9 In contrast, CaMKII may be even involved in the pathogenesis of hypertrophy and HF because CaMKII transgenic mice develop severe HF. 10 There is a direct association of CaMKII and the RyR2 increasing diastolic SR Ca 2ϩ leak despite (or actually leading to) reduced SR Ca 2ϩ load in CaMKII transgenic mice. 10, 11 SR Ca 2ϩ leak could be markedly reduced by CaMKII inhibition in this mouse HF model, as well as in rabbit HF models, providing evidence for a direct relation between CaMKII activity and reduced SR Ca 2ϩ load caused by increased Ca 2ϩ spark frequency. 10,12,13 Since Kirchhefer et al reported that CaMKII activity was increased in the left ventricles (LVs) of HF patients with dilated cardiomyopathy (DCM) in 1999, 9 nothing was published about the role of CaMKII in human failing myocardium. Moreover, the function of CaMKII and its regulatory mechanisms in the failing heart are still a controversial issue. Because all functional studies to date were performed in animal models and knowledge about regional CaMKII expression in human myocardium is rare, it remains unclear whether and how CaMKII inhibition actually alters intracellular Ca 2ϩ handling and myocardial contractility. Thus, the present study investigated CaMKII expression in DCM and ischemic cardiomyopathy (ICM) human LV and right ventricle (RV) myocardium. The second objective was to determine the functional effects of CaMKII by pharmacological CaMKII inhibition in HF.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Human Myocardial Tissue
Experiments were performed with myocardium from 43 end-stage failing hearts (New York Heart Association heart failure classification IV; ICM, nϭ25; DCM, nϭ15; other, nϭ3) and 12 nonfailing (NF) donor hearts that could not be transplanted for technical reasons. Control subjects had no history of heart disease and had normal LV function.
Large Animal Model
Four sheep were sedated with Telazol (6 mg/kg) and were endotracheally intubated. Anesthesia was maintained with 1% to 2% isoflurane. The hearts were explanted via a left thoracotomy, which was performed through the fourth intercostal space.
Trabeculae Preparation and Experiments
Thin ventricular trabeculae were isolated from the RV of human end-stage failing hearts. 14 -16 For isometric force recordings, trabeculae were superfused with Krebs-Henseleit solution and connected to a force transducer.
Myocyte Isolation
Chunk isolation was performed with LV myocardial slices using collagenase (Worthington type 2; 250 U/mg) and trypsin (25% trypsin). Only elongated cells with cross-striations and without granulation were selected for experiments.
Intracellular Ca 2؉ Imaging

Measurement of Ca 2؉ Sparks
Isolated myocytes were incubated with 10 mol/L Fluo-3AM, which also contained either CaMKII inhibitors or control. Ca 2ϩ spark measurements were performed with a laser-scanning confocal microscope. During continuous superfusion of the chamber, spark frequency was measured after loading the SR with Ca 2ϩ by repetitive field stimulation. Ca 2ϩ spark size was calculated as product of amplitude (F/F 0 ), duration and width. From this, we inferred the average leak per cell by multiplication of Ca 2ϩ spark size with the mean spark frequency of the respective cell.
Determination of SR Ca 2؉ Content
Myocytes were field stimulated at 1 Hz, and SR Ca 2ϩ content was assessed by caffeine-induced Ca 2ϩ transients. These amplitudes were used as a measure for SR Ca 2ϩ content. 16 
Western Blots
Ventricular myocardium was homogenized. Protein concentration was determined by BCA assay (Pierce Biotechnology). Denatured tissue was subjected to Western blotting using different antibodies. Chemiluminescent detection was performed with Immobilion Western (Millipore). Phosphorylation values were normalized to protein expression.
Data Analysis and Statistics
Force values were normalized to the cross-sectional area of the trabeculae (widthϫthicknessϫ/4) and expressed in mN/mm 2 . All data are expressed as meansϮSEM. Student's t test or 2-way repeated-measures ANOVA with Holm-Sidak tests were used to test for significance. A value of PϽ0.05 was considered significant.
Results
CaMKII Expression in Human Heart Failure
To further extend the knowledge about CaMKII␦ expression and distribution between LV and RV, we performed expres- Figure 1B ). Furthermore, we show that ICM is also associated with significantly upregulated CaMKII␦ expression in both heart chambers ( Figure 1C and 1D 
Effects of CaMKII Inhibition on Contractility
Functional experiments were always performed using paired isolated trabeculae of the same area of the same heart. Twitch force was not different at baseline conditions (1 Hz) before incubation with the compounds being 6.6Ϯ1.6 mN/mm 2 for the KN-92 control group and 6.8Ϯ1.1 mN/mm 2 for those that were incubated with KN-93 (nϭ14 trabeculae of 9 hearts each, Pϭ0.9).
Because it is known that CaMKII activity increases with higher frequencies, we obtained force frequency relationships Values are normalized to GAPDH and finally to NF myocardium, which was also normalized to GAPDH before. *PϽ0.05 vs nonfailing.
(FFR) in trabeculae stimulated at frequencies that varied between 0.5 to 3 Hz (Figure 2A and 2B). 16 Whereas basal contractility at 0.5 Hz was unchanged in CaMKII inhibited trabeculae (4.6Ϯ0.9 versus 4.2Ϯ0.8 mN/mm 2 for KN-93, Pϭ0.78), twitch force amplitude was largely increased at higher stimulation frequencies. Figure 2A and 2B shows original registrations of trabeculae stimulated at increasing frequencies in the presence of KN-92 or KN-93. The rather negative FFR in KN-92 control trabeculae changed to a positive FFR in trabeculae in KN-93-treated trabeculae. Twitch force amplitude increased by 92Ϯ20% for KN-93 and only by 10Ϯ13% for KN-92 at 2 Hz and by 101Ϯ33% versus Ϫ4Ϯ15% at 3 Hz (both frequencies PϽ0.05 and ANOVA PϽ0.05 compared with KN-92, nϭ14/9 each; Figure 2C ). Of note, the significant increase in force amplitude of KN-93-treated trabeculae was also significant regarding peak force values (data not shown). Also, to exclude unspecific effects of KN-92 (eg, on LTCC), we performed FFR experiments without any drug showing very similar results as compared with KN-92 (data not shown).
In contrast, the beneficial effect of CaMKII inhibition was not associated with significant alterations of diastolic tension at increasing frequencies ( Figure 2D ).
Similarly, we did not find any influence of CaMKII inhibition on relaxation kinetics of the trabeculae with frequency-dependent acceleration of relaxation being found in both groups to a similar extent ( Figure 2E ).
To confirm our findings, we additionally performed FFRs using AIP and did found comparable effects ( Figure 2F ). Twitch force amplitude increased by 52Ϯ14% for AIP and only by 9Ϯ11% for controls at 2 Hz (ANOVA PϽ0.05, nϭ9 each; Figure 2G ), whereas diastolic tension and relaxation time were not statistically changed ( Figure 2H and 2I). Control twitch force values of this series are very similar to those that were observed in the presence of KN-92.
Because fresh human NF myocardium is difficult to obtain, we performed experiments with NF myocardium from a large animal. Interestingly we did not see a positive inotropic effect in sheep trabeculae in the presence of KN-93 compared with KN-92 ( Figure 3A) . Twitch force amplitude relative to 0.5 at 2 Hz was 205Ϯ48% for KN-93 and 171Ϯ32% for KN-92 (ANOVA Pϭ0.67, nϭ6 each; Figure 2B ), and diastolic tension was unchanged ( Figure 3C ). Figure 3D shows that there was a trend toward a slower relaxation time in the presence of KN-93 that however did not reach statistical significance.
SR Ca 2؉ Load Is Increased Because of Inhibition of CaMKII
Periods of 10, 30, and 120 seconds of rest were evaluated and the first twitch was normalized to the last twitch before rest. Original registrations in Figure 4A show that postrest behavior was significantly improved in the presence of KN-93. This effect was more pronounced after long rest intervals. The first twitches after 120 seconds of rest normalized to the last twitches before rest were more than doubled, with an average of 2.5Ϯ0. 4 Figure 5B ). Moreover, experiments presented in Figure 5C revealed that the Ca 2ϩ spark duration was also slightly reduced in the presence of KN-93 (71.7Ϯ1.2 versus 68.0Ϯ1.3 ms for KN-92, PϽ0.05). This leads to a significant decrease in total calculated SR Ca 2ϩ leak in CaMKII-inhibited myocytes by 30% (PϽ0.05; Figure 5D ). Experiments were repeated using another CaMKII inhibitor AIP (55 myocytes versus 51 serving as controls). A total of 47% of the measured myocytes developed SR Ca 2ϩ sparks under control conditions and only 29% in AIP-treated cells ( Figure 5E and 5F). The total calculated SR Ca 2ϩ leak was significantly reduced by 39% in the presence of AIP ( Figure 5H ). Detailed SR Ca 2ϩ spark parameters are presented in Table 2 .
Altered Phosphorylation Status During CaMKII Inhibition
To verify the efficacy of the used CaMKII inhibitors, we performed phosphorylation analysis in CaMKII-inhibited trabeculae. A FFR was performed in the presence of KN-93 versus KN-92 or AIP versus control and specimen were immediately frozen away. As presented in Figure 6A , KN-93 led to a downphosphorylation of CaMKII at Thr286 of 65.8Ϯ11.2% (PϽ0.05, nϭ7 each) and in AIP-treated homogenated specimen of 83.1Ϯ8.2% (PϽ0.05, nϭ4 each; Figure 6B ).
Because relaxation kinetics were unchanged during CaMKII inhibition, we also investigated CaMKII effects on PLB. The CaMKII phosphorylation site at Thr17 of PLB (monomer) was not significantly altered after treatment with KN-93, as presented in Figure 6C (Pϭ0.48, nϭ8 each) . Similar results were obtained by investigation of a proposed CaMKII phosphorylation site at the LTCC ␤ 2a subunit (Thr498). 17 The common p-CaMKII (Thr286) antibody was shown to detect CaMKII-dependent phosphorylation of the LTCC ␤ 2a subunit. 17 In the same trabeculae where CaMKII phosphorylation was significantly depressed after treatment with KN-93, we found an unchanged Thr498 phosphorylation status between KN-93-and KN-92-treated trabeculae (nϭ4 each; Figure 6D ).
Finally, we were interested whether the observed effects on SR Ca 2ϩ leak are mediated via modulation of the RyR2 phosphorylation status. CaMKII is considered to phosphorylate Ser2815 18 rather than Ser2809, which may be also phosphorylated by protein kinase (PK)A. 19 -21 In CaMKII-inhibited homogenates versus controls, RyR2 phosphorylation (normalized to RyR2 protein levels) was increased at both Ser2809 and Ser2815 sites. Figure 6E shows that CaMKII inhibition lead to a 42.6Ϯ9.8% (nϭ5/3 each, PϽ0.05) decrease of RyR2 phosphorylation at Ser2809 and a more pronounced effect at the CaMKII specific binding site Ser2815 of 74.0Ϯ11.3% (nϭ3/2 each, PϽ0.05; Figure 6F ). Thus, our results suggest that decreased SR Ca 2ϩ leak resulting from CaMKII inhibition may be attributable to reduced RyR2 phosphorylation.
Discussion
This study demonstrates for the first time that inhibition of elevated CaMKII levels in human end-stage failing but not in sheep NF myocardium significantly improves cardiac contractility. CaMKII␦ B and ␦ C protein levels were significantly increased in ICM and DCM in both LV as well as RV myocardium. CaMKII-inhibitor-dependent positive inotropic effects that occurred during FFR were elucidated by performing postrest experiments, caffeine measurements, and determination of SR Ca 2ϩ leak. SR Ca 2ϩ load was significantly improved most likely because of a reduced SR Ca 2ϩ leak during CaMKII inhibition. The mechanism responsible for this may be the reduced RyR2 phosphorylation at Ser2809 and Ser2815.
CaMKII in the Failing Heart
During excitation-contraction coupling, CaMKII phosphorylates several Ca 2ϩ -handling proteins. Thus, CaMKII can substantially modulate Ca 2ϩ influx and SR Ca 2ϩ release and uptake. After PLB phosphorylation via CaMKII or PKA, SERCA activity and SR Ca 2ϩ uptake can be enhanced, leading to faster relaxation of the myocytes. Because of the increased CaMKII expression in human failing myocardi- um it has been proposed that elevated CaMKII in HF plays a compensatory role to keep myocardium from complete failure. 9, 22 However, in recent years evidence arose that increased levels of CaMKII may have actually adverse effects as it was shown that CaMKII overexpression in a transgenic mouse model leads to cardiac hypertrophy and severe DCM. 10, 11 Moreover, a rabbit model of nonischemic HF indicated that CaMKII-dependent phosphorylation of the RyR2 is involved in enhanced SR Ca 2ϩ leak and reduced SR Ca 2ϩ load and thus may contribute to arrhythmias and contractile dysfunction in the failing heart. 13 We have recently shown that in human atrial fibrillation where CaMKII levels are also elevated, CaMKII increases SR Ca 2ϩ leak, potentially contributing to arrhythmias. 23 The results of the present study show that increased CaMKII in human HF is not limited to LV from patients with DCM as it was initially shown. 9, 22 In fact, we found that CaMKII is also increased in ischemic origins and also in the RV of ICM as well as DCM. Thus, it appears that in the majority of end-stage HF etiologies CaMKII increases independently of the genesis, which might be a general phenomenon and therefore important for further in vivo investigations.
CaMKII Inhibition in Human Failing Myocardium
Here, we demonstrate that inhibition of CaMKII increases contractility in the human failing myocardium with a more pronounced effect at higher stimulation-frequencies. This effect was not observed in NF sheep trabeculae. Postrest potentiation together with caffeine experiments revealed that this observation can be explained by an increased SR Ca 2ϩ load in the presence of CaMKII inhibitors in human failing myocardium.
To understand the mechanism behind this finding we investigated SR Ca 2ϩ leak in freshly isolated myocytes. SR Ca 2ϩ leak together with reduced SERCA activity is considered to be a major contributor to contractile dysfunction in HF by losing Ca 2ϩ from the SR and consequently from the intracellular milieu probably via increased Na ϩ /Ca 2ϩ exchanger. 24 As a measure for SR Ca 2ϩ leak we found that SR Ca 2ϩ spark frequency is highly sensitive to KN-93 although the reduced total SR Ca 2ϩ leak is more driven by the markedly diminished Ca 2ϩ spark frequency than be effects on spark duration as confirmed by experiments using AIP. This finding is in agreement with previous reports showing transgenic overexpression of CaMKII being associated with reduced SR Ca 2ϩ load caused by increased SR Ca 2ϩ leak. 10 Most importantly, these effects could be reversed by KN-93 in our study. Obviously, SR 
Ca
2ϩ leak can be reduced independent of the species, cause, or amount of CaMKII expression because overexpression in the latter transgenic mouse model was more than 10-fold compared with control conditions and in the present study CaMKII expression was increased by only 30% to 40%. Also, Ai et al investigated effects of CaMKII on SR Ca 2ϩ -function in a rabbit model of nonischemic HF. 13 In this model, CaMKII was found to hyperphosphorylate the RyR2 leading to increased SR Ca 2ϩ leak and reduced SR Ca 2ϩ load. By inhibiting CaMKII using KN-93, these authors showed that SR Ca 2ϩ -content as well as Ca 2ϩ transients could be increased. 13 In the present study we attribute the reduced SR Ca 2ϩ leak in the presence of KN-93 to a reduced phosphorylation of the RyR2 at the CaMKII specific binding site (Ser2815) and to a lesser extent, at Ser2809 which can also be phosphorylated by PKA. Wehrens et al performed site-directed mutagenesis and identified an exclusive CaMKII-specific binding site at Ser2815 on recombinant RyR2. 18 However, previous studies have suggested that Cardiomyocytes were either treated with KN-92 vs KN-93 or AIP vs control. RT50 indicates time from peak to 50% of relaxation; RT90, time from peak to 90% of relaxation; TTP, time to peak. *PϽ0.05 vs the corresponding control group (KN-92 or control).
Ser2809 may be the phosphorylation site of both PKA and CaMKII based on sequencing of tryptic phosphopeptides 20, 25 or a phosphoepitope-specific antibody.
Interestingly, we found that inhibition of CaMKII lacks effects on relaxation kinetics in our experiments. Accordingly, Western blot analysis of PLB revealed unchanged phosphorylation status at Thr17 after treatment with KN-93. Until recently, there was a general agreement that CaMKII phosphorylates PLB at Thr17 leading to improved frequency-dependent acceleration of relaxation. 26 Because of this, our finding with respect to unchanged relaxation and CaMKII-mediated PLB phosphorylation is in part surprising, although it has been previously observed that acute CaMKII overexpression neither changed relaxation of cell shortening nor the Ca 2ϩ transient decay in rabbit myocytes. 27 One possible explanation for CaMKII inhibition leading to marked dephosphorylation of the RyR2, without changes in LTCC or PLB phosphorylation and relaxation in human failing hearts, may be that compartmentalization of protein phosphatase (PP)1 and/or protein phosphatase inhibitor-1 (I-1) plays a crucial role in the phosphorylation/dephosphorylation balance of the cell. It has been proposed that differential anchoring of PP1 to various compartments can explain differences between RyR2 and PLB phosphorylation in HF. 19 Moreover, it was shown that SR-associated PP1 activity is increased 2.5-fold, suggesting that I-1 preferentially localize to the SR. 28 El-Armouche et al found a good correlation between PLB and I-1 phosphorylation in human HF supporting the notification of a causal relationship and arguing for preferential affection of PLB (at the free SR) compared with the RyR2 located at the junctional SR. 29 Taken together, CaMKII-induced phosphorylation effects via PLB may be ameliorated, whereas phosphorylation of the RyR2 may be excessive in human heart failure. Thus, inhibition of CaMKII rather exerts effects on SR Ca 2ϩ release in HF similar to our finding of an improved SR Ca 2ϩ leak in human atrial fibrillating myocardium. 23 Even if there might be slight effects on relaxation which may not be detectable with our techniques the SR Ca 2ϩ leak would counteract small increases of faster Ca 2ϩ uptake. In any case, it seems that the major detrimental effect of CaMKII in HF and consequently the most important target emerging from our study is CaMKII-mediated SR Ca 2ϩ leak, which greatly outbalanced possible detrimental effects attributable to reduced SERCA-activity on CaMKII inhibition.
Recently, it was reported that knocking out the CaMKII-S2814 phosphorylation site on the RyR in a mouse model decreases the positive inotropic response to an increase of stimulation frequency which is just the opposite of what we have found. 30 This finding is in sharp contrast to our results but could be explained by different excitation-contraction coupling of species and possible allosteric effects on the CaMKII-S2814 knockout model.
Because CaMKII is known to phosphorylate LTCCs, we investigated one of the proposed CaMKII phosphorylation sites of the ␤ 2a subunit at Thr498. 17 Whereas CaMKII phosphorylation was found to be markedly depressed in KN-93-treated trabeculae, we did not find any changes at the LTCC ␤ 2a subunit. Although not intensively studied, this finding (if Thr498 is the corresponding phosphorylation site in human myocardium) could explain why the positive inotropic effect caused by a reduced SR Ca 2ϩ leak may not be counteracted by CaMKII-dependent LTCC modulation. Nevertheless, the LTCC ␤ 2a subunit phosphorylation site of CaMKII has not been studied in human myocardium and thus requires further intensive research.
Another finding of our study is an unchanged diastolic tension during CaMKII inhibition, although diastolic tension increases with raising frequencies. This might be largely attributed to a strong correlation between fibrosis and diastolic dysfunction in the human heart, 31 which cannot be influenced by acute ionic modulation.
Limitations of the Study
It must be stated that evaluation of CaMKII effects was acute and pharmacologically performed. Therefore, chronic effects of CaMKII inhibition (eg, on target protein expression or transcription) cannot be ruled out.
KN-93 has been reported to exert unspecific effects (eg, on LTCC). 32 However, this may be disregarded from our results, because this effect of KN-93 on I Ca is shared by its inactive analog KN-92 32 and we did not observe phosphorylation changes at the proposed binding site of CaMKII at the ␤ 2a subunit of LTCC 17 between KN-93-and KN-92-treated trabeculae. Moreover, we recently found similar effects of KN-93 and KN-92 on I Ca in human atrial myocytes. 23 In particular, we confirmed our findings by using AIP in trabeculae, as well as in isolated cardiomyocytes. AIP is known to be CaMKII-specific. 32 Additionally, effectiveness of CaMKII inhibition was confirmed by performing tissue phosphorylation analysis after treatment with KN-93, as well as AIP. It has to be stated that the phospho-CaMKII antibody may not distinguish between different CaMKII isoforms. Because CaMKII␥ was also found to be upregulated in human HF, we attribute our functional findings to inhibition of CaMKII without any specifications of the isoform. In the present work, CaMKII expression was investigated without evaluation of CaMKII phosphorylation, which has been previously done in human failing hearts. 9 This decision is based on the fact that reasonable phosphorylation analysis requires shock freezing of tissue within minutes. This may not be maintained after heart explantation especially for NF hearts, which also serve as valve donors and are dissected over some period of time.
Paired RV trabeculae were used in the present study, because LV endocardium consists of a large amount of fibrosis and thus may not be representative of the mean mass of wall myocardium, at least for the functional experiments. One further advantage in using RV trabeculae is that LV myocardium is largely spared from infarction and previous ischemia. To allow the assessment of CaMKII inhibition in RV preparations, CaMKII expression was investigated in the presented study, and no differences were found between CaMKII expression in the RV as compared with the LV. This may be caused by the fact that end-stage failing hearts often undergo severe pump failure of both ventricles.
During CaMKII inhibition, we found a reduced phosphorylation of Thr286 of Ϸ70% to 80%. Thus, our model represents no ablation of CaMKII because residual active CaMKII can still phosphorylate target proteins. Finally, we found a reduced SR Ca 2ϩ leak as the potential mechanism causing positive inotropic effects in the presence of CaMK inhibitors. However, another mechanism that may contribute to these effects, either by CaMKII-dependent mechanisms or by the inhibitors that were used, cannot be completely ruled out.
Summary and Conclusion
In summary, the present study shows for the first time that CaMKII inhibition improves contractile function in human end-stage failing myocardium, where CaMKII␦ expression is increased. CaMKII-dependent RyR2 phosphorylation leads to increased SR Ca 2ϩ leak, depleting the SR of Ca 2ϩ . CaMKII inhibition reduces this Ca 2ϩ leak, resulting in positive inotropic effects observed in our functional experiments. Because CaMKII also plays a role in structural remodeling, 33, 34 CaMKII inhibition should be further clini-cally investigated with respect to providing novel strategies and therapies in human HF.
